Adding Elotuzumab to Myeloma Treatment Regimens Does Not Improve Outcomes
Predictors of worse progression-free survival included ISS stage II, ISS stage III, and adverse cytogenetics.
Hematologic Cancers
Copiktra Indication for Relapsed/Refractory Follicular Lymphoma Withdrawn
The Company will be working with the FDA in the coming weeks to complete the label revision process.
FDA Approves Rituxan Plus Chemotherapy for Certain Pediatric Hematologic Cancers
The approval was based on data from the open-label, randomized phase 3 Inter-B-NHL Ritux 2010 trial.
Parsaclisib Under Review for Follicular, Marginal Zone, and Mantle Cell Lymphomas
The application is supported by data from several phase 2 studies.
Brukinsa Approved for Waldenström Macroglobulinemia
The approval was based on data from the phase 3 ASPEN trial.
Dosing Schedule of Intravenous Bisphosphonate Has Little Effect on Recurrent Skeletal-Related Events in Patients With Multiple Myeloma
No significant difference in SRE risk on the basis of intravenous bisphosphonate dosing was observed for patients with newly diagnosed multiple myeloma.
MPR Weekly Dose Podcast 84
The FDA grants Emergency Use to Actemra to treat hospitalized COVID patients. Revisions are been made to the fact sheets for the Moderna and Pfizer BioNTech COVID vaccines to include information related to the risk of myocarditis and pericarditis. A new treatment is approved for some cancer patients allergic to E. coli-Derived asparaginase products. Meanwhile,…
Anti-CLL1 CAR T Cells Produce Responses in Pediatric Acute Myeloid Leukemia
Eight patients had a complete response within 1 month of infusion.
Model May Identify Non-ETP T-ALL Patients at High Risk of Poor Response to Treatment
The model appears to predict minimal residual disease status.
Response-Based Ponatinib Dosing Appears Effective in Chronic Phase Chronic Myeloid Leukemia
A 45-mg starting dose, reduced to 15 mg, produced the best outcome.
